Remove 2025 Remove HIV Treatment and Prevention Agents Remove Labelling
article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

IDStewardship

AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.

article thumbnail

Year In Review: Top Infectious Diseases Articles From 2024

IDStewardship

I wonder if this will cause us to be more fragmented as a group in 2025 and if Bluesky will really have sticking power. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | NEJM PURPOSE 1 RCT : No participants receiving twice-yearly lenacapavir acquired HIV infection. Mastodon sure did not.